

RealRate

PHARMACEUTICAL 2018











PHARMACEUTICAL 2018



RealRate

ANAPTYSBIO INC Rank 10 of 342

The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 45% points. The greatest weakness of ANAPTYSBIO INC is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 298%, being 253% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	252,696
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,090
Liabilities, Non-Current	0
Other Assets	76,003
Other Compr. Net Income	-426
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,289
Other Revenues	10,000
Property and Equipment	665
Research and Development	29,443
Selling, General and Administrative Expense	9,338

Output Variable	Value in 1000 USD
Assets	329,364
Liabilities	14,090
Expenses	38,781
Revenues	10,000
Stockholders Equity	315,274
Net Income	-30,070
Comprehensive Net Income	-30,283
Economic Capital Ratio	298%

